XML 50 R32.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies - Additional Information (Details) - USD ($)
 1 Months Ended 12 Months Ended
Aug. 31, 2022
Jan. 01, 2022
Apr. 30, 2018
Dec. 31, 2022
Dec. 31, 2021
Loss Contingencies [Line Items]          
Operating lease right-of-use asset $ 300,000     $ 363,000  
Operating lease liability, current $ 300,000     168,000  
Operating leases, rent expense       200,000 $ 300,000
Variable lease payments       0  
Short-term lease costs       $ 0  
Remaining lease term       2 years  
Incremental borrowing rate used to determine operating lease liability       6.50%  
Teva Agreements          
Loss Contingencies [Line Items]          
Nonrefundable upfront payment     $ 6,000,000.0    
Payment upon achievement of certain clinical and commercial milestones     135,000,000.0    
Asset transfer and license agreement, termination period after written notice       120 days  
Asset transfer and license agreement, termination period notice of breach       60 days  
Asset transfer and license agreement termination notice period if bankruptcy petition filed       60 days  
Milestone payments       $ 0 0
Teva Agreements | Research and Development Expenses          
Loss Contingencies [Line Items]          
Milestone payments       $ 0 $ 0
Teva Agreements | Teva's GlycoPEGylated FGF21 Program          
Loss Contingencies [Line Items]          
Payment upon achievement of certain clinical and commercial milestones     67,500,000    
Teva Agreements | Teva's Development Program          
Loss Contingencies [Line Items]          
Payment upon achievement of certain clinical and commercial milestones     $ 67,500,000    
San Francisco Office          
Loss Contingencies [Line Items]          
Operating lease expiration month and year 2025-01 2023-01